NextPoint Therapeutics
Cambridge
About NextPoint Therapeutics
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $122.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2024)
- Website: nextpointtx.com
- Phone: 508-204-1115
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nextpoint-therapeutics-53982 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.